Impact of Advanced Hybrid Closed Loop on Youth With High-Risk Type 1 Diabetes Using Multiple Daily Injections
| Autor: | Alisa Boucsein, Antony S. Watson, Carla M. Frewen, Olivia J. Sanders, Jillian J. Haszard, Shirley D. Jones, Philippa J. Milford-Hughes, Martin I. de Bock, Benjamin J. Wheeler |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Diabetes Care. 46:628-632 |
| ISSN: | 1935-5548 0149-5992 |
| DOI: | 10.2337/dc22-1971 |
| Popis: | OBJECTIVETo evaluate glycemic outcomes in youth (aged 13–25 years) with type 1 diabetes and high-risk glycemic control (HbA1c ≥8.5% [69 mmol/mol]) on multiple daily injection (MDI) therapy after transitioning to advanced hybrid closed loop (AHCL) therapy.RESEARCH DESIGN AND METHODSThis prospective, 3-month, single-arm, dual-center study enrolled 20 participants, and all completed the study.RESULTSHbA1c decreased from 10.5 ± 2.1% (91.2 ± 22.8 mmol/mol) at baseline to 7.6 ± 1.1% (59.7 ± 11.9 mmol/mol), and time spent in target range 70–180 mg/dL (3.9–10.0 mmol/L) increased from 27.6 ± 13.2% at baseline to 66.5 ± 9.8% after 3 months of AHCL. Two episodes of diabetic ketoacidosis attributed to infusion set failure occurred.CONCLUSIONSAHCL has the potential to improve suboptimal glycemia in youth with type 1 diabetes previously on MDI therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|